Corium International,Inc. (NASDAQ:CORI) Files An 8-K Results of Operations and Financial Condition
Item2.02.Results of Operations and Financial Condition.
On February 13, 2017, Corium International, Inc. (the Company)
issued a press release to announce its financial results for its
first quarter ended December 31, 2016.A copy of the press release
is furnished as Exhibit 99.1 to this report and is incorporated
herein by reference.
The information furnished with this report, including Exhibit
99.1, shall not be deemed filed for purposes of Section 18 of the
Securities Exchange Act of 1934, as amended (the Exchange Act),
or otherwise subject to the liabilities of that section, nor
shall it be deemed incorporated by reference into any other
filing under the Securities Act of 1933, as amended, or the
Exchange Act, except as expressly set forth by specific reference
in such a filing.
Item9.01.Financial Statements and Exhibits.
(d)Exhibits.
|
Exhibit Number |
Description |
|
99.1 |
Press release dated February 13, 2017. |
2
About Corium International, Inc. (NASDAQ:CORI)
Corium International, Inc. is a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty pharmaceutical products. As of September 30, 2016, the Company had multiple programs in preclinical and clinical development focused primarily on the treatment of neurological disorders, with two lead programs in Alzheimer’s disease. The Company has two transdermal platforms: Corplex for small molecules and MicroCor, a biodegradable microstructure technology for small molecules and biologics, including vaccines, peptides and proteins. Its late-stage pipeline includes a contraceptive patch, which has completed Phase III trials, and additional transdermal products that are being developed with other partners. Its products include Clonidine TDS, Fentanyl TDS and Crest Whitestrips. Its pipeline products include Twirla, Corplex Donepezil and Corplex Memantine, Donepezil, Corplex Ropinerole, MicroCor hPTH(1-34) and Motion Sickness Patch. Corium International, Inc. (NASDAQ:CORI) Recent Trading Information
Corium International, Inc. (NASDAQ:CORI) closed its last trading session up +0.06 at 2.89 with 82,489 shares trading hands.